Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Geoffrey L. Ray"'
Autor:
Diane E. Milenic, Paul S. Albert, Martin W. Brechbiel, Lanea M. M. Keller, Kwamena E. Baidoo, Geoffrey L. Ray
Publikováno v:
Pharmaceuticals, Vol 5, Iss 1, Pp 1-15 (2011)
Studies from this laboratory have demonstrated the potential of targeting HER2 for therapeutic and imaging applications with medically relevant radionuclides. To expand the repertoire of trastuzumab as a radioimmunoconjugate (RIC) vector, use of 177L
Externí odkaz:
https://doaj.org/article/6eb640d509954333a4982b381e5814b7
Autor:
Vadim Moskvin, A Gautam, Indra J. Das, Geoffrey L. Ray, Chee-Wai Cheng, Jeffrey C. Buchsbaum, Foster D. Lasley
Publikováno v:
Journal of Radiation Oncology. 3:195-203
Objective The purpose of this retrospective study is to determine the dependence of acute skin toxicity on physical parameters associated with the proton beam treatment.
Autor:
Kwamena E. Baidoo, Diane E. Milenic, Martin W. Brechbiel, Lanea M. M. Keller, Paul S. Albert, Geoffrey L. Ray
Publikováno v:
Pharmaceuticals; Volume 5; Issue 1; Pages: 1-15
Pharmaceuticals, Vol 5, Iss 1, Pp 1-15 (2011)
Pharmaceuticals
Pharmaceuticals, Vol 5, Iss 1, Pp 1-15 (2011)
Pharmaceuticals
Studies from this laboratory have demonstrated the potential of targeting HER2 for therapeutic and imaging applications with medically relevant radionuclides. To expand the repertoire of trastuzumab as a radioimmunoconjugate (RIC) vector, use of (177
Publikováno v:
Molecular Pharmaceutics. 9:374-381
Herein we report the preparation along with the in vivo and in vitro MRI characterization of two generation four and five cystamine core dendrimers loaded with thirty and fifty-eight derivatized Gd-DOTA (G4SS30, G5SS58) respectively. Likewise the dev
Autor:
Marcia L. Wills, Zachary Lopater, Jerry J. Jaboin, Bo Lu, Misun Hwang, Geoffrey L. Ray, Qiuyin Cai, Heidi Chen, Carmen A. Perez
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 79:1330-1335
To evaluate whether selected high-risk matrix metalloproteinase-7 single nucleotide polymorphisms influence clinicopathologic outcomes in patients with early-stage prostate cancer.Two hundred twelve prostate cancer patients treated with radical prost
Autor:
Michael Williams, Kayhan Garmestani, Geoffrey L. Ray, Martin W. Brechbiel, Diane E. Milenic, Kwamena E. Baidoo, Karen J. Wong
Publikováno v:
British Journal of Pharmacology. 157:1541-1548
The studies described here are the first to evaluate the in vitro and in vivo properties of (111)In-CHX-A''-panitumumab for radioimmunotherapy (alpha- and beta(-)-emitters) and radioimmunoimaging (single photon emission computed tomography and positr
Publikováno v:
Nanotechnology for Biomedical Imaging and Diagnostics: From Nanoparticle Design to Clinical Applications
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e2c9606dadf9196e77d11269040797b7
https://doi.org/10.1002/9781118873151.ch8
https://doi.org/10.1002/9781118873151.ch8
Autor:
Matthew Hines, R. Victor Simoneaux, Jeffrey C. Buchsbaum, Kevin P. McMullen, James G. Douglas, Peter A.S. Johnstone, Geoffrey L. Ray
Publikováno v:
Pediatric Blood & Cancer. 60:1839-1841
Background Uniquely in children, the existence of leptomeningeal spinal metastases does not confer a uniformly grave prognosis. Although the radiation tolerance of the spinal cord is of significant concern in these cases, the chemo- and radiosensitiv
Autor:
Geoffrey L, Ray, Jeffrey C, Buchsbaum, Kevin P, McMullen, R Victor, Simoneaux, Matthew, Hines, James G, Douglas, Peter A S, Johnstone
Publikováno v:
Pediatric bloodcancer. 60(11)
Uniquely in children, the existence of leptomeningeal spinal metastases does not confer a uniformly grave prognosis. Although the radiation tolerance of the spinal cord is of significant concern in these cases, the chemo- and radiosensitivity of thes
Autor:
Mark R. Williams, Diane E. Milenic, Karen J. Wong, Martin W. Brechbiel, Kayhan Garmestani, Geoffrey L. Ray, Kwamena E. Baidoo
Publikováno v:
Cancer biotherapyradiopharmaceuticals. 23(5)
The monoclonal antibody, cetuximab, binds to epidermal growth-factor receptor and thus provides an opportunity to create both imaging and therapies that target this receptor. The potential of cetuximab as a radioimmunoconjugate, using the acyclic bif